PMC:7170368 / 170-1062
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 18 | 538-542 | Gene | denotes | IL-6 | Gene:3569 |
| 19 | 615-618 | Gene | denotes | CD8 | Gene:925 |
| 20 | 116-124 | Species | denotes | patients | Tax:9606 |
| 21 | 327-335 | Species | denotes | patients | Tax:9606 |
| 22 | 427-435 | Species | denotes | patients | Tax:9606 |
| 23 | 865-873 | Species | denotes | patients | Tax:9606 |
| 24 | 75-96 | Disease | denotes | coronavirus infection | MESH:D018352 |
| 25 | 106-114 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 26 | 318-326 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 27 | 341-353 | Disease | denotes | hypertension | MESH:D006973 |
| 28 | 856-864 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 29 | 879-891 | Disease | denotes | hypertension | MESH:D006973 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T1 | 557-562 | Body_part | denotes | blood | http://purl.org/sig/ont/fma/fma9670 |
| T2 | 621-625 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
| T3 | 647-652 | Body_part | denotes | blood | http://purl.org/sig/ont/fma/fma9670 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T2 | 23-47 | Body_part | denotes | renin-angiotensin system | http://purl.obolibrary.org/obo/UBERON_0018229 |
| T3 | 49-52 | Body_part | denotes | RAS | http://purl.obolibrary.org/obo/UBERON_0018229 |
| T4 | 138-141 | Body_part | denotes | RAS | http://purl.obolibrary.org/obo/UBERON_0018229 |
| T5 | 394-397 | Body_part | denotes | RAS | http://purl.obolibrary.org/obo/UBERON_0018229 |
| T6 | 557-562 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
| T7 | 647-652 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T3 | 87-96 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T4 | 106-114 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T5 | 318-326 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T6 | 341-353 | Disease | denotes | hypertension | http://purl.obolibrary.org/obo/MONDO_0005044 |
| T7 | 454-457 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
| T8 | 585-588 | Disease | denotes | ARB | http://purl.obolibrary.org/obo/MONDO_0012733 |
| T9 | 856-864 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T10 | 879-891 | Disease | denotes | hypertension | http://purl.obolibrary.org/obo/MONDO_0005044 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 54-57 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T2 | 470-471 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T3 | 506-507 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T4 | 521-522 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T5 | 557-562 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
| T6 | 557-562 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | blood |
| T7 | 607-610 | http://purl.obolibrary.org/obo/CLO_0052882 | denotes | CD3 |
| T8 | 607-610 | http://purl.obolibrary.org/obo/CLO_0053434 | denotes | CD3 |
| T9 | 615-618 | http://purl.obolibrary.org/obo/CLO_0053438 | denotes | CD8 |
| T10 | 619-625 | http://purl.obolibrary.org/obo/CL_0000084 | denotes | T cell |
| T11 | 647-652 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
| T12 | 647-652 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | blood |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T3 | 29-40 | Chemical | denotes | angiotensin | http://purl.obolibrary.org/obo/CHEBI_48433 |
| T4 | 49-52 | Chemical | denotes | RAS | http://purl.obolibrary.org/obo/CHEBI_63620 |
| T5 | 138-141 | Chemical | denotes | RAS | http://purl.obolibrary.org/obo/CHEBI_63620 |
| T6 | 142-152 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T7 | 162-202 | Chemical | denotes | angiotensin-converting enzyme inhibitors | http://purl.obolibrary.org/obo/CHEBI_35457 |
| T8 | 162-173 | Chemical | denotes | angiotensin | http://purl.obolibrary.org/obo/CHEBI_48433 |
| T9 | 185-202 | Chemical | denotes | enzyme inhibitors | http://purl.obolibrary.org/obo/CHEBI_23924 |
| T10 | 192-202 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T11 | 204-209 | Chemical | denotes | ACEIs | http://purl.obolibrary.org/obo/CHEBI_35457 |
| T12 | 215-229 | Chemical | denotes | angiotensin II | http://purl.obolibrary.org/obo/CHEBI_2719|http://purl.obolibrary.org/obo/CHEBI_48432|http://purl.obolibrary.org/obo/CHEBI_58506 |
| T15 | 215-226 | Chemical | denotes | angiotensin | http://purl.obolibrary.org/obo/CHEBI_48433 |
| T16 | 227-229 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
| T17 | 394-397 | Chemical | denotes | RAS | http://purl.obolibrary.org/obo/CHEBI_63620 |
| T18 | 398-408 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T19 | 538-540 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T21 | 705-727 | Chemical | denotes | antihypertensive drugs | http://purl.obolibrary.org/obo/CHEBI_35674 |
| T22 | 722-727 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T23 | 773-778 | Chemical | denotes | ACEIs | http://purl.obolibrary.org/obo/CHEBI_35457 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T7 | 0-317 | Sentence | denotes | The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. |
| T8 | 318-409 | Sentence | denotes | COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. |
| T9 | 410-563 | Sentence | denotes | We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. |
| T10 | 564-728 | Sentence | denotes | In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. |
| T11 | 729-892 | Sentence | denotes | This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension. |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T2 | 341-353 | Phenotype | denotes | hypertension | http://purl.obolibrary.org/obo/HP_0000822 |
| T3 | 879-891 | Phenotype | denotes | hypertension | http://purl.obolibrary.org/obo/HP_0000822 |